
ROCHE HOLDING LTD ORD by Roche rose 26.8% from $378.00 to $479.42, ahead of the S&P 500's +10.0%. Its worst day was Jan 8 (−7.6%), and its low came Mar 20 at $375.75.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare providers to act quickly and prevent severe complications and onward transmission.Detects and differentiates between three
+11.7%, the year's best day
Story events cover the past 12 months · Times ET
- A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss
+9.9% · S&P 500 +0.4%
ROCHE HOLDING LTD ORD by Roche closed at its lowest level of the year, 0.6% below where the year started.
−6.1% · S&P 500 −1.4%
ROCHE HOLDING LTD ORD by Roche shares rose 9.3%, while the S&P 500 rose 0.2%.
+9.3% · S&P 500 +0.2%
Where it ended: a close of $479.42 on Nov 17, 2026.
Nothing in the past 12 months.
All RHHBF earningsNothing in the past 12 months.
All RHHBF analyst actionsNothing in the past 12 months.
All RHHBF dividend history